1. "Robert Motzer"
Formats
  1. Journal Article (609)
  2. Meeting Abstract (574)
  3. Book Section (20)
  4. Review (13)
  5. Conference Paper (6)
  6. Correspondence (6)
  7. Guidelines (5)
  8. Research Letter (5)
  9. Editorial (3)
  10. Book Whole (2)
Groups
  1. Department of Medicine (1243)
  2. Genitourinary Oncology Service (1243)
  3. Solid Tumor Oncology Division (1243)
  4. Surgery (288)
  5. Urology (279)
  6. Survivorship Research (252)

More Groups

People
  1. Robert Motzer (1243)
  2. George Bosl (182)
  3. Martin Voss (176)
  4. Darren Feldman (157)
  5. Dean Bajorin (128)
  6. Paul Russo (119)

More People

Years
  1. 2025 (26)
  2. 2024 (49)
  3. 2023 (47)
  4. 2022 (64)
  5. 2021 (65)
  6. 2020 (65)

More Years

Publications
  1. Journal of Clinical Oncology (444)
  2. Annals of Oncology (81)
  3. BJU International (40)
  4. Cancer (35)
  5. European Journal of Cancer (34)
  6. Clinical Cancer Research (33)

More Publications

Publishers
  1. American Society of Clinical Oncology (447)
  2. Elsevier Science, Inc. (111)
  3. Oxford University Press (111)
  4. Elsevier Inc. (89)
  5. Wiley Blackwell (86)
  6. American Association for Cancer Research (58)

More Publishers

Results (1243)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pathway convergent evolution underscores treatment response to MTOR inhibitors in kidney cancers
    Meeting Abstract

    Voss, M. H.; Hakimi, A. A.; Pham, C. G.; Brannon, A. R.; Chen, Y. B.; Cunha, L. F.; Akin, O.; Liu, H.; Takeda, S.; Scott, S. N.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save
  • Long-term safety with sunitinib (SU) in metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Porta, C.; Gore, M. E.; Rini, B. I.; Escudier, B.; Charles, L. P.; Chen, L.; Hariharan, S.; Motzer, R. J.
    European Journal of Cancer (2013)

    Fulltext@MSK | Save
  • Treatment sequencing following first-line sunitinib in patients (pts) with advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Gore, M. E.; Hutson, T. E.; Lin, X.; Korytowsky, B.; Lechuga, M. J.; Matczak, E.; Figlin, R. A.; Bukowski, R.; Motzer, R. J.
    European Journal of Cancer (2013)

    Fulltext@MSK | Save
  • Safety and efficacy of second-line axitinib versus sorafenib in metastatic renal cell carcinoma by duration of prior therapy: Subanalyses from a phase III trial
    Meeting Abstract

    Escudier, B.; Motzer, R. J.; Lim, H. Y.; Porfiri, E.; Zalewski, P.; Kannourakis, G.; Tarazi, J.; Rosbrook, B.; Kim, S.; Rini, B. I.
    European Journal of Cancer (2013)

    Fulltext@MSK | Save
  • Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial
    Journal Article

    Motzer, R. J.; Nosov, D.; Eisen, T.; Bondarenko, I.; Lesovoy, V.; Lipatov, O.; Tomczak, P.; Lyulko, O.; Alyasova, A.; Harza, M.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma
    Journal Article

    Hakimi, A. A.; Furberg, H.; Zabor, E. C.; Jacobsen, A.; Schultz, N.; Ciriello, G.; Mikkilineni, N.; Fiegoli, B.; Kim, P. H.; Voss, M. H.; more...
    JNCI: Journal of the National Cancer Institute (2013)

    Fulltext@MSK | Save
  • A phase 3 comparative study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus everolimus in patients with advanced or metastatic renal cell carcinoma (mRCC) previously treated with anti-angiogenic therapy
    Meeting Abstract

    Motzer, R. J.; Bono, P.; Tomita, Y.; Ravaud, A.; Waxman, I.; Gore, M. E.
    BJU International (2013)

    Fulltext@MSK | Save
  • A phase 3 randomized study of cabozantinib (XL184) vs everolimus in subjects with clear cell renal cell carcinoma (METEOR)
    Meeting Abstract

    Choueiri, T. K.; Escudier, B.; Powles, T.; Cella, D.; Lee, Y.; Laird, D. A.; Scheffold, C.; Motzer, R. J.
    BJU International (2013)

    Fulltext@MSK | Save
  • Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial
    Journal Article

    Stein, A.; Bellmunt, J.; Escudier, B.; Kim, D.; Stergiopoulos, S. G.; Mietlowski, W.; Motzer, R. J.
    European Urology (2013)

    Fulltext@MSK | Save
  • Pazopanib versus sunitinib in renal cancer - The authors reply
    Journal Article

    Motzer, R. J.; McCann, L.; Deen, K.
    New England Journal of Medicine (2013)

    Fulltext@MSK | Save